Alcohol
Highest phase reached
Approved
Drug type
Small molecule
First approval year
1982
- First approval year
- 1982
- Listing at source
- Listed
- Highest phase reached
- Approved
- Drug type
- Small molecule
- Drug name
- Alcohol
- Molecular weight
- 46.07
- Structure (SMILES)
- ablysinol
- Ablysinol
- alcohol component of avagard
- Alcohol component of avagard
- alcohol component of hbn 1 ethanol
- Alcohol component of hbn-1 ethanol
- methylated mineral
- Methylated mineral
- spirigel
- Spirigel
- surg
- Surg
- alcohol
- Alcohol
- Alcohol (Ethanol)
- Alcohol (oral)
- Alcohol (Oral)
- ALCOHOL [HSDB]
- ALCOHOL [II]
- ALCOHOL [MART.]
- ALCOHOL [ORANGE BOOK]
- ALCOHOL [USP-RS]
- ALCOHOL [VANDF]
- ALCOHOL [WHO-IP]
- alcohol 190 proof
- Alcohol 190 proof
- alcohol 95
- Alcohol 95%
- alcohol absolute
- alcohol anhydrous
- Alcohol anhydrous
- alcohol dehydrated
- alcohol dehydrated ii
- alcohol dehydrated vandf
- alcohol denat
- Alcohol denat.
- alcohol denatured
And 137 more, listed on the interactive page.
- CAS registry numbers
- 64-17-5
- ChEMBL ID
- CHEMBL545
- InChIKey
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N
- PubChem compound IDs
- 702
- RxNorm IDs (RxCUI)
- 448
- FDA ingredient codes (UNII)
- 3K9958V90M
- D08AX08
- V03AB16
- V03AZ01
Sources for recorded values
- Applicant
- SOLVENTUM
- Approval date
- 7 Jun 2001
- Application number
- NDA021074
- Patents
- 0
- Designations
- 2
- Earliest recorded loss of exclusivity
- 23 Oct 2032
- First in class
- No
- Fast track
- No
- Breakthrough designation
- No
- Orphan designation
- No
- Priority review
- No
- Orphan exclusivity
- No
- Accelerated approval
- No
- Availability
- Over the counter
- Pharmacology name
- ethanol
- Type
- Metabolite
Administration routes
- Parenteral
- topical
- Action type
- ACTIVATION
- Target
- TRPV6
- Gene symbol
- TRPV6
- Action
- Activation
- Action type
- ACTIVATION
- Target
- TRPV6
- Gene symbol
- TRPV6
- Protein identifier
- Q9H1D0
- Median affinity
- 0.82
- Affinity units
- pEC50
- Action
- Potentiation
- Action type
- POTENTIATION
- Target
- Glycine Receptor (All subtypes)
- Gene symbol
- Glycine Receptor (All subtypes)
- Condition
- Atrial Fibrillation
- Highest recorded phase
- 2
- Condition identifier
- EFO:0000275
- Subject identifier
- D001281
- Condition
- Prostatic Hyperplasia
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000284
- Subject identifier
- D011470
- Condition
- Hypertension
- Highest recorded phase
- 3
- Condition identifier
- EFO:0000537
- Subject identifier
- D006973
- Condition
- Infections
- Highest recorded phase
- 4
- Condition identifier
- EFO:0000544
- Subject identifier
- D007239
- Condition
- Neuroblastoma
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000621
- Subject identifier
- D009447
- Condition
- Endometriosis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:0001065
- Subject identifier
- D004715
- Condition
- Obesity
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001073
- Subject identifier
- D009765
- Condition
- Liver Cirrhosis
- Highest recorded phase
- 2
- Condition identifier
- EFO:0001422
- Subject identifier
- D008103
- Condition
- Bacteremia
- Highest recorded phase
- 3
- Condition identifier
- EFO:0003033
- Subject identifier
- D016470
- Condition
- Renal Insufficiency, Chronic
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003884
- Subject identifier
- D051436
- Condition
- Acne Vulgaris
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003894
- Subject identifier
- D000152
- Condition
- Erectile Dysfunction
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004234
- Subject identifier
- D007172
- Condition
- Alcohol Drinking
- Highest recorded phase
- 1
- Condition identifier
- EFO:0004329
- Subject identifier
- D000428
- Condition
- Neurobehavioral Manifestations
- Highest recorded phase
- 2
- Condition identifier
- EFO:0004364
- Subject identifier
- D019954
- Condition
- Tachycardia, Ventricular
- Highest recorded phase
- 2
- Condition identifier
- EFO:0005306
- Subject identifier
- D017180
- Condition
- Marijuana Abuse
- Highest recorded phase
- 1
- Condition identifier
- EFO:0007191
- Subject identifier
- D002189
- Condition
- Burns
- Highest recorded phase
- 4
- Condition identifier
- EFO:0009516
- Subject identifier
- D002056
- Condition
- Central Nervous System Neoplasms
- Highest recorded phase
- 2
- Condition identifier
- EFO:1000158
- Subject identifier
- D016543
- Condition
- Neoplasms, Cystic, Mucinous, and Serous
- Highest recorded phase
- 1
- Condition identifier
- EFO:1000889
- Subject identifier
- D018297
- Condition
- Prediabetic State
- Highest recorded phase
- 3
- Condition identifier
- EFO:1001121
- Subject identifier
- D011236
- Condition
- Pulpitis
- Highest recorded phase
- 0.5
- Condition identifier
- EFO:1001139
- Subject identifier
- D011671
- Condition
- Herpes Labialis
- Highest recorded phase
- 2
- Condition identifier
- EFO:1001347
- Subject identifier
- D006560
- Condition
- Thyroid Nodule
- Highest recorded phase
- 1
- Condition identifier
- EFO:1001436
- Subject identifier
- D016606
- Condition
- Hyperhidrosis
- Highest recorded phase
- 1
- Condition identifier
- HP:0000975
- Subject identifier
- D006945
- Condition
- Tremor
- Highest recorded phase
- 2
- Condition identifier
- HP:0001337
- Subject identifier
- D014202
And 18 more, listed on the interactive page.
- Condition identifier
- EFO_0000182
- Condition identifier
- EFO_0000275
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000284
- Condition identifier
- EFO_0000537
- Highest recorded phase
- 3
- Condition identifier
- EFO_0000544
- Condition identifier
- EFO_0000544
- Highest recorded phase
- 4
- Condition identifier
- EFO_0000621
- Highest recorded phase
- 1
- Condition identifier
- EFO_0000641
- Condition identifier
- EFO_0000764
- Condition identifier
- EFO_0001065
- Condition identifier
- EFO_0003033
- Highest recorded phase
- 3
- Condition identifier
- EFO_0003884
- Highest recorded phase
- 2
- Condition identifier
- EFO_0003894
- Highest recorded phase
- 2
- Condition identifier
- EFO_0004234
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004318
- Highest recorded phase
- 1
- Condition identifier
- EFO_0004329
- Condition identifier
- EFO_0004364
- Highest recorded phase
- 2
- Condition identifier
- EFO_0005279
- Condition identifier
- EFO_0005306
- Highest recorded phase
- 3
- Condition identifier
- EFO_0009516
- Condition identifier
- EFO_0009516
- Highest recorded phase
- 4
- Condition identifier
- EFO_0009574
- Highest recorded phase
- 2
- Condition identifier
- EFO_0010582
- Condition identifier
- EFO_0801084
- Condition identifier
- EFO_1000025
And 55 more, listed on the interactive page.
- Event
- acidosis
- Reports
- 32
- Reporting signal score
- 56.0882
- Event
- aggression
- Reports
- 166
- Reporting signal score
- 276.489
- Event
- agitation
- Reports
- 185
- Reporting signal score
- 247.184
- Event
- alcohol abuse
- Reports
- 198
- Reporting signal score
- 895.909
- Event
- alcohol interaction
- Reports
- 57
- Reporting signal score
- 210.583
- Event
- alcohol poisoning
- Reports
- 101
- Reporting signal score
- 415.255
- Event
- alcohol use
- Reports
- 92
- Reporting signal score
- 316.015
- Event
- alcohol withdrawal syndrome
- Reports
- 32
- Reporting signal score
- 113.401
- Event
- alcoholism
- Reports
- 48
- Reporting signal score
- 121.54
- Event
- amnesia
- Reports
- 88
- Reporting signal score
- 96.4713
- Event
- anti-cyclic citrullinated peptide antibody positive
- Reports
- 35
- Reporting signal score
- 82.9541
- Event
- blood alcohol increased
- Reports
- 29
- Reporting signal score
- 118.595
- Event
- blood creatine phosphokinase increased
- Reports
- 66
- Reporting signal score
- 54.0256
- Event
- coma
- Reports
- 289
- Reporting signal score
- 625.661
- Event
- completed suicide
- Reports
- 26
- Reporting signal score
- 94.1595
- Event
- confusional state
- Reports
- 150
- Reporting signal score
- 91.9908
- Event
- depressed level of consciousness
- Reports
- 89
- Reporting signal score
- 95.5609
- Event
- drug abuse
- Reports
- 403
- Reporting signal score
- 908.047
- Event
- drug abuser
- Reports
- 34
- Reporting signal score
- 67.9682
- Event
- drug dependence
- Reports
- 179
- Reporting signal score
- 391.717
- Event
- drug hypersensitivity
- Reports
- 836
- Reporting signal score
- 1,323.41
- Event
- drug screen positive
- Reports
- 32
- Reporting signal score
- 63.7635
- Event
- drug use disorder
- Reports
- 28
- Reporting signal score
- 57.0434
- Event
- drug withdrawal syndrome
- Reports
- 114
- Reporting signal score
- 155.745
- Event
- duodenal ulcer perforation
- Reports
- 35
- Reporting signal score
- 89.7073
And 38 more, listed on the interactive page.
- NCT00001925
- NCT00006656
- NCT00009854
- NCT00037141
- NCT00247585
- NCT00290290
- NCT00680459
- NCT01101412
- NCT01472965
- NCT02227329
- NCT02577718
- NCT03083184
- NCT03253887
- NCT03640507
- NCT03757143
- NCT03838575
- NCT05268419
- NCT00295334
- NCT00437606
- NCT00471679
- NCT00563342
- NCT00616746
- NCT03294460
- NCT03361384
- NCT04159688
And 53 more, listed on the interactive page.
- Discard after use
- Keep out of reach of children
- Use on hands when no soap and water available
- Hydrogen bond acceptors
- 1
- Hydrogen bond donors
- 1
- Polar surface area
- 20.23
- Calculated partition coefficient (ALogP)
- 0
- Calculated partition coefficient (XLogP)
- -0.1
- Prodrug
- No
- Chirality
- Achiral
- Inorganic
- No
- Rule-of-five violations
- 0
- Rotatable bonds
- 0
- Heavy atoms
- 3
- Molecular formula
- C2H6O
- Monoisotopic mass
- 46.041864811
- Natural product
- Yes
- 16729-710
- 50742-539
- 51991-999
- 54288-105
- 54288-144
- 55579-306
- 82983-426
- 83634-306
- 39822-9300
- 50090-7643
- Recorded assays
- 3,468
- Active assays
- 17
Active assay types
- Other
- Anti-Infective Agents, Local
- Central Nervous System Depressants
- Solvents
Distribution coefficient (LogD)
- Median
- -0.31
- Mean
- -0.31
- Minimum
- -0.31
- Maximum
- -0.31
- Unit
- unitless
- Assays
- 1
- Standard deviation
- 0
- Summary method
- median
- Censored results excluded
- 0
- Other units excluded
- 0
- Unknown units excluded
- 0
Measurement types
- LogD
Related records
Trials (328)
- A Clinical Trial to Evaluate the Efficacy and Safety of CKD-495
- A Long-term Follow-up Study in Patients Who Received BEAM-101
- A Prospective Study of EUS Guided Celiac Block
- A Real-World Study of Pyrrolitinib Maleate Tablets for HER-2-Positive Early or Locally Advanced Breast Cancer After Adjuvant Trastuzumab Therapy
- A Study in Healthy Subjects to Determine the Effects When Alcohol is Administered With Perampanel
- A Study of a Hydrocolloid Bandage on Pimples
- A Study of ALKS 8700, a Monomethyl Fumarate (MMF) Molecule, in Healthy Adults
- A Study of Booster Immunization With COVID-19 Vaccine,Inactivated Co -Administration With Influenza Vaccine and Pneumococcal Polysaccharide Vaccine
- A Study of LY4057996 in Healthy Participants and Participants With Type 1 and Type 2 Diabetes
- A Study of the Hemodynamic Interactions of TPN171H Tablets & Alcohol in Healthy Male Subjects
- A Study of the Pharmacokinetics/Pharmacodynamics of GK Activator (2) in Type 2 Diabetes Patients With Hepatic Impairment.
- A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects
- A Study to Assess the Effects of ACI-24.060 in Alzheimer's Disease and in Down Syndrome (ABATE Study)
- A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects
- A Study to Determine the Influence of Co-ingestion of Alcohol on Hydrocodone Bitartrate Extended Release (HC-ER)
- A Study to Evaluate the Immunogenicity and Safety of Nonavalent Human Papillomavirus (HPV) Vaccine
- A Systems Approach to Understanding Disease Processes in Multiple Sclerosis
- A Two-part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KRP203 in Patients Undergoing Stem Cell Transplant for Hematological Malignancies
- A5288/MULTI-OCTAVE: Management Using Latest Technologies to Optimize Combination Therapy After Viral Failure
- Acute Effects of Alcohol on PET Imaging of Phosphodiesterase-4B (PDE4B)
Approved for (1)
- Burn
In development for (34)
- Acne Phase 2
- Alcohol abuse Phase 3
- Alcohol dependence Phase 3
- Alcohol-related disorders Phase 1
- Alopecia Phase 2
- Atrial fibrillation Phase 2
- Bacterial infectious disease with sepsis Phase 3
- Benign prostatic hyperplasia Phase 1
- Bipolar disorder Phase 2
- Cannabis dependence Phase 1
- Central nervous system neoplasm Phase 2
- Chronic kidney disease Phase 2
- Cirrhosis of liver Phase 2
- Constipation disorder Phase 2
- COVID-19 Phase 3
- Cystic, mucinous, and serous neoplasm Phase 1
- Dysmenorrhea Phase 2
- Endometriosis Early phase 1
- Erectile dysfunction Phase 1
- Essential hypertension Phase 2
Other linked conditions (6)
- Cystitis
- Hepatocellular carcinoma
- HIV infectious disease
- Nosocomial infection
- Temporomandibular joint disorder
- Thyroid gland papillary carcinoma